The pan-European BSL-4 research infrastructure
ERINHA (European Research Infrastructure on Highly Pathogenic Agents) is a pan-European Research Infrastructure dedicated to study high-consequence pathogens of Risk Group 4 (RG4). As a distributed Research infrastructure it brings together leading European biosafety level 4 (BSL-4) facilities and national research institutes with longstanding experience of research in this field. Such a coordinated approach is vital in the context marked by frequent globalization of infectious diseases with high risk for public health, society and economy. The overarching goal of ERINHA’s Infrastructure research concept is to provide capacities to conduct projects which are broad in scope, ambition and require a wide range of capabilities inside and outside BSL-4 facility that no single facility can provide on its own.
The access to the ERINHA is organized through its Central Coordinating Unit, hosted in Paris.
The ERINHA’s Research Portfolio is an evolving strategy built on the WHO Research and Development Blueprint with systematic updates to match with European and Global Research and Innovation and Public Health needs. The current prioritized agents are the following: Ebola, Marburg, Lassa, Crimean-Congo Hemorrhagic Fever, Nipah/Hendra, Unknown agents.
ERINHA’s research approach ranges from discovery to prevention on the field of highly pathogenic agents. The main fields are to provide diagnostic capabilities, increase the understanding of the diseases, develop new interventions and translate them to the market demands.
Read more: https://www.erinha.eu/research-strategy
Read more: https://www.erinha.eu/governance
Catalogue of service
- Open access policy to ERINHA Infrastructure;
- Supporting participating national BSL-4 facilities in the event of a surge of requirements for BSL-4 capacities;
- Assisting and advising in design, construction, operation and maintenance of a new or additional BSL-3 or BSL-4 facility;
- Advising on biosafety and biosecurity fields;
- Matching experimental studies to users’ needs (basic virology, studies of viral pathogenesis using animal models and evaluation of antivirals and vaccines);
- Training new users in the member BSL-4 facilities.